These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 11436116)

  • 1. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.
    Champlin R; Khouri I; Anderlini P; Gajewski J; Kornblau S; Molldrem J; Shimoni A; Ueno N; Giralt S
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S13-22. PubMed ID: 11436116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
    Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.
    Banna GL; Aversa S; Sileni VC; Favaretto A; Ghiotto C; Monfardini S
    Crit Rev Oncol Hematol; 2004 Sep; 51(3):171-89. PubMed ID: 15331077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.
    Espinoza-Delgado I; Childs RW
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):865-75. PubMed ID: 15485320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience.
    Shimoni A; Nagler A
    Curr Hematol Rep; 2004 Jul; 3(4):242-8. PubMed ID: 15217553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia.
    Qazilbash MH; Giralt SA; Champlin RE
    Hematol Oncol Clin North Am; 2004 Jun; 18(3):703-13, xi. PubMed ID: 15271401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-myeloablative stem cell transplant].
    Shoji N; Mineishi S
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):795-800. PubMed ID: 10897204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
    Giralt S
    Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
    Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic haemopoietic stem cell transplantation using non-myeloablative conditioning--a local experience.
    Leong CF; Cheong SK; Fadilah SA; Ainoon O; Hamidah NH
    Med J Malaysia; 2003 Jun; 58(2):229-35. PubMed ID: 14569743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
    Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
    J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches.
    Friedman TM; Varadi G; Hopely DD; Filicko J; Wagner J; Ferber A; Martinez J; Brunner J; Grosso D; McGuire L; Korngold R; Flomenberg N
    Biol Blood Marrow Transplant; 2001; 7(12):656-64. PubMed ID: 11787528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can reduced-intensity allogeneic transplantation cure older adults with AML?
    Storb R
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):85-90. PubMed ID: 17336258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
    Saito TI; Rubio MT; Sykes M
    Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Lekakis L; de Lima M
    Expert Rev Anticancer Ther; 2008 May; 8(5):785-98. PubMed ID: 18471050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonmyeloablative allogeneic stem cell transplantation for acute leukemia.
    Laport GG
    Curr Hematol Rep; 2003 Jan; 2(1):49-56. PubMed ID: 12901154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.